<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371604</url>
  </required_header>
  <id_info>
    <org_study_id>2355-005</org_study_id>
    <secondary_id>IDX-08C-005</secondary_id>
    <secondary_id>2011-001878-25</secondary_id>
    <nct_id>NCT01371604</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)</brief_title>
  <official_title>A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and antiviral activity of IDX184 in
      combination with pegylated interferon and ribavirin in treatment-naïve subjects with genotype
      1 chronic hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who experience a serious adverse event</measure>
    <time_frame>Up to Week 16 and end of treatment (Weeks 24 or 48)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experience an adverse event</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experience a grade 1-4 laboratory abnormality</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who achieve undetectable HCV ribonucleic acid (RNA) viral levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve undetectable HCV RNA viral levels at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve undetectable HCV RNA viral levels at the end of treatment</measure>
    <time_frame>Weeks 24 or 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve sustained virologic response (SVR)</measure>
    <time_frame>24 weeks after the last dose (Weeks 48 or 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve HCV RNA viral levels below the lower level of quantification (LLOQ) at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve HCV RNA viral levels below LLOQ at the end of treatment</measure>
    <time_frame>Weeks 24 or 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve HCV RNA viral levels below LLOQ at follow-up (24 weeks after the last dose)</measure>
    <time_frame>Weeks 48 or 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>IDX184 50 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 100 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX184</intervention_name>
    <description>IDX184 50 mg tablet administered orally</description>
    <arm_group_label>IDX184 50 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a (Peg-IFN)</intervention_name>
    <description>Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly</description>
    <arm_group_label>IDX184 50 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg + Peg-IFN/RBV</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.</description>
    <arm_group_label>IDX184 50 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>IDX184 100 mg + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to IDX184 50 mg tablet administered orally</description>
    <arm_group_label>IDX184 50 mg + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females with documented genotype 1, chronic hepatitis C infection.

          -  Must agree to use double-barrier method of birth control for at least 6 months after
             the last dose of study drugs.

          -  Has not received prior antiviral treatment for HCV.

          -  Written informed consent by participant.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen [HBsAg] positive)
             and/or human immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

